Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression.

Marilyn KaulAhmed Y SaninWenjie ShiChristoph JaniakUlf Dietrich Kahlert

Published in: Pharmacological reports : PR (2024)

Nanofunctionalization of DASA needs further improvement to overcome the therapy resistance of PDAC. LYN mRNA is augmented in tumors with higher malignancy and can serve as a predictive biomarker for the therapy resistance of PDAC cells against DASA. Studying the biological roles of BLK might help to identify underlying molecular mechanisms associated with PDAC in diabetic patients.

Keyphrases

induced apoptosis
binding protein
cell proliferation
cell death
cell cycle arrest
mesenchymal stem cells
signaling pathway
oxidative stress
tyrosine kinase
pi k akt
chemotherapy induced